Bionano Genomics Inc (NASDAQ: BNGO) is a life sciences instrumentation company in genome analysis. It is engaged in developing and marketing the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and streamline the study of changes in chromosomes.

Key Highlights 

• Elevated Net Losses: Despite clocking healthy growth in revenue by 112.0% to USD 4.7 million in Q3FY21, BNGO failed to minimize its net loss, which increased to USD 20.8 million, compared to USD 10.8 million in pcp. This exhibits the pressure on the company.
• Clocked Higher Operating Expenses: With continued investment in sales and marketing, as well as research and development, the company's operational expenses grew to USD 21.8 million, up to USD 10.9 million or 99.1% from USD 11.0 million in Q3FY20.
• Negative Cash Flows: For 9MFY21, the company reported cash used in operating activities of USD 46.3 million, higher than USD 26.2 million in the previous corresponding period. We believe this was primarily due to net losses which occurred in the period.

Source: Company

• Lower Margin Profile v/s Industry: In Q3FY21, the company failed to maintain its pace and witnessed lower performance across the operating matrix. The company is clocking negative margins on multiple fronts, exhibiting operational pressure.

Financial overview of Q3FY21 (in USD)

Source: Company

• The company announced its quarterly result, wherein it posted total revenue of USD 4.7 million, a surge from USD 2.2 million in pcp. The growth was supported by both of the company's revenue segments.

• Total cost of revenue jumped to USD 3.5 million, from USD 1.5 million in pcp.

• The company's operating expenses increased by 99.1% to USD 21.8 million against USD 11.0 million in pcp. Higher selling, general and administrative expenses, and higher R&D expenses were the main reasons.

• Primarily on the back of the above-discussed rationales, the company's net loss increased to USD 20.8 million, compared to USD 10.8 million in pcp.

Risks Associated with Investment 

Because the corporation is losing money from its current activities, new capital must sustain its growth ambitions. Furthermore, any delays in regulatory clearances would harm the company's overall success.

Stock Recommendation

In Q3FY21, the company recorded a positive topline but failed to maintain the trend in its bottom line. Furthermore, its operations have been hampered by an increase in input costs due to the new acquisition. In addition, the management stated that the travel limitation imposed on account of COVID-19 hurt the company's operations and that further restrictions would represent a threat to its prospects. The stock of BNGO declined ~38.98% and ~41.11% in the last one month and six months, respectively. It closed below the immediate support levels of 50-days and 100-days simple moving averages (SMA), respectively, indicating a bearish pattern. Hence considering the above facts, we recommend a "Watch" rating on the stock at the closing price of USD 3.71 on December 02, 2021.

One-Year Technical Price Chart (as on December 02, 2021). Source: REFINITIV, Analysis by Kalkine Group

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.